PE20070437A1 - FORMULACION ACUOSA hFSH - Google Patents
FORMULACION ACUOSA hFSHInfo
- Publication number
- PE20070437A1 PE20070437A1 PE2006001144A PE2006001144A PE20070437A1 PE 20070437 A1 PE20070437 A1 PE 20070437A1 PE 2006001144 A PE2006001144 A PE 2006001144A PE 2006001144 A PE2006001144 A PE 2006001144A PE 20070437 A1 PE20070437 A1 PE 20070437A1
- Authority
- PE
- Peru
- Prior art keywords
- formulation
- hfsh
- aqueous formulation
- human follicle
- stimulation hormone
- Prior art date
Links
- 239000013011 aqueous formulation Substances 0.000 title abstract 2
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 title 1
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 239000005556 hormone Substances 0.000 abstract 2
- 229940088597 hormone Drugs 0.000 abstract 2
- 230000000638 stimulation Effects 0.000 abstract 2
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 229920001213 Polysorbate 20 Polymers 0.000 abstract 1
- 229930003836 cresol Natural products 0.000 abstract 1
- 230000009027 insemination Effects 0.000 abstract 1
- 239000007951 isotonicity adjuster Substances 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 abstract 1
- 239000008363 phosphate buffer Substances 0.000 abstract 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract 1
- 229940068977 polysorbate 20 Drugs 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA FORMULACION ACUOSA QUE COMPRENDE: A) LA HORMONA DE ESTIMULACION DEL FOLICULO HUMANO (hFSH) DE ORIGEN NATURAL O RECOMBINADO; B) GLICINA QUE SE ENCUENTRA EN UNA CANTIDAD DE 0,1% HASTA 10% P/V DE LA FORMULACION; C) METIONINA QUE SE ENCUENTRA EN UNA CANTIDAD DE 0,01% HASTA 2% P/V DE LA FORMULACION; D) UN SURFACTANTE NO IONICO TAL COMO EL POLISORBATO 20 QUE SE ENCUENTRA EN UNA CANTIDAD DE 0,001% HASTA 0,02% P/V DE LA FORMULACION; E) BUFFER DE FOSFATO COMO ESTABILIZADOR QUE TIENE UN pH DE 6,5 A 7,5; F) UN CONSERVANTE TAL COMO CRESOL, ALCOHOL DE BENCIL, ENTRE OTROS; Y OPCIONALMENTE G) UN AGENTE ISOTONICO TAL COMO MANITOL, SORBITOL, GLICEROL, ENTRE OTROS. DICHA COMPOSICION PERMITE LA ESTABILIDAD DE LA HORMONA DE ESTIMULACION DEL FOLICULO HUMANO (FSH) DURANTE UN PERIODO DE TIEMPO PROLONGADO MANTENIENDO SU ACTIVIDAD TERAPEUTICA SIENDO UTIL PARA LA ASPIRACION DE OVULO EN LA INSEMINACION ARTIFICIAL Y EL TRATAMIENTO DE INFERTILIDAD
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020050089853A KR101105871B1 (ko) | 2005-09-27 | 2005-09-27 | 인 난포자극호르몬의 안정한 용액 제형 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070437A1 true PE20070437A1 (es) | 2007-04-26 |
Family
ID=37899985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006001144A PE20070437A1 (es) | 2005-09-27 | 2006-09-21 | FORMULACION ACUOSA hFSH |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20110201554A1 (es) |
| EP (1) | EP1928413B1 (es) |
| JP (1) | JP5364374B2 (es) |
| KR (1) | KR101105871B1 (es) |
| CN (1) | CN101272764B (es) |
| AR (1) | AR056538A1 (es) |
| AT (1) | ATE466570T1 (es) |
| AU (1) | AU2006295570B2 (es) |
| BR (1) | BRPI0616300A2 (es) |
| DE (1) | DE602006014175D1 (es) |
| ES (1) | ES2345058T3 (es) |
| GT (1) | GT200600431A (es) |
| PE (1) | PE20070437A1 (es) |
| RU (1) | RU2407514C2 (es) |
| SA (1) | SA06270332B1 (es) |
| TR (1) | TR200801968T2 (es) |
| TW (1) | TW200735897A (es) |
| WO (1) | WO2007037607A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8617568B2 (en) | 2007-07-10 | 2013-12-31 | Medy-Tox, Inc. | Pharmaceutical liquid composition of botulinum toxin with improved stability |
| NZ586590A (en) | 2008-01-09 | 2012-06-29 | Sanofi Aventis Deutschland | Insulin analogues or derivatives having an extremely delayed time-action profile |
| RS52106B (sr) | 2008-02-08 | 2012-08-31 | Biogenerix Ag | Tečni preparat fsh |
| PL3228320T3 (pl) | 2008-10-17 | 2020-06-01 | Sanofi-Aventis Deutschland Gmbh | Kombinacja insuliny i agonisty GLP-1 |
| CN102202682B (zh) | 2008-11-04 | 2015-08-19 | Aska制药株式会社 | 含促卵泡激素的水性组合物 |
| DK2498801T3 (en) | 2009-11-13 | 2018-05-07 | Sanofi Aventis Deutschland | PHARMACEUTICAL COMPOSITION INCLUDING desPro36Exendin-4 (1-39) -Lys6-NH2 AND METHIONIN |
| SI2554183T1 (en) | 2009-11-13 | 2018-08-31 | Sanofi-Aventis Deutschland Gmbh | A pharmaceutical composition comprising the GLP-1 agonist and insulin and methionine |
| EP2533800B1 (en) * | 2010-02-12 | 2016-07-20 | Intas Pharmaceuticals Ltd. | Liquid formulation of follicle stimulating hormone |
| EP2417982A1 (en) * | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
| KR101823320B1 (ko) | 2010-08-30 | 2018-01-31 | 사노피-아벤티스 도이칠란트 게엠베하 | 제２형 진성 당뇨병 치료용 약제를 제조하기 위한 ａｖｅ００１０의 용도 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| DK2750699T3 (en) | 2011-08-29 | 2015-10-26 | Sanofi Aventis Deutschland | A pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
| CA2928311A1 (en) * | 2013-11-12 | 2015-05-28 | Cadila Healthcare Limited | Formulation for gonadotropins |
| WO2015104314A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| KR20160104726A (ko) | 2014-01-09 | 2016-09-05 | 사노피 | 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형 |
| CA2932873A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
| TN2017000235A1 (en) | 2014-12-12 | 2018-10-19 | Sanofi Aventis Deutschland | Insulin glargine/lixisenatide fixed ratio formulation |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| GB201603280D0 (en) * | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
| JP2020002130A (ja) * | 2018-06-25 | 2020-01-09 | Ｊｃｒファーマ株式会社 | 蛋白質含有水性液剤 |
| CN115429751B (zh) * | 2022-09-21 | 2023-11-17 | 景泽生物医药(合肥)股份有限公司 | 一种人重组卵泡刺激素注射剂及其制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270057A (en) * | 1990-03-20 | 1993-12-14 | Akzo N.V. | Stabilized gonadotropin containing preparations |
| IT1250075B (it) * | 1991-12-18 | 1995-03-30 | Serono Cesare Ist Ricerca | Composizioni farmaceutiche contenenti gonadotropine. |
| RU2062619C1 (ru) * | 1994-02-08 | 1996-06-27 | Курский сельскохозяйственный институт им.проф.И.И.Иванова | Способ получения препарата фолликулостимулирующего гормона из аденогипофизов животных |
| PT814841E (pt) * | 1995-03-21 | 2002-03-28 | Applied Research Systems | Formulacoes liquidas de hcg |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| TW518235B (en) * | 1997-01-15 | 2003-01-21 | Akzo Nobel Nv | A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage |
| JP4719357B2 (ja) * | 1998-07-23 | 2011-07-06 | アレス トレイディング ソシエテ アノニム | Ｆｓｈ及びｆｓｈ変異体の製剤、製品及び方法 |
| HK1039065B (en) * | 1999-04-08 | 2004-04-16 | Genentech, Inc. | Composition based on oppositely-charged polypeptides |
| US7514239B2 (en) * | 2000-03-28 | 2009-04-07 | Amgen Inc. | Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof |
| US20020058029A1 (en) * | 2000-09-18 | 2002-05-16 | Nabil Hanna | Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination |
| IL161677A0 (en) * | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| AU2003217367B2 (en) * | 2002-02-08 | 2005-09-08 | Alkermes Controlled Therapeutics, Inc. | Polymer-based compositions for sustained release |
| US20050232899A1 (en) * | 2002-05-31 | 2005-10-20 | Aradigm Corporation | Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b |
| CN1195069C (zh) * | 2002-11-28 | 2005-03-30 | 南京医科大学 | 人卵泡刺激素β亚基单克隆抗体的制备方法 |
| PL1610822T5 (pl) * | 2003-04-02 | 2019-05-31 | Ares Trading Sa | Płynne formulacje farmaceutyczne FSH i LH z niejonowym surfaktantem |
| US20060069021A1 (en) * | 2004-08-13 | 2006-03-30 | Nastech Pharmaceutical Company Inc. | Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs |
| MY139088A (en) * | 2005-02-21 | 2009-08-28 | Lg Life Sciences Ltd | Sustained release composition of protein drug |
| CN101217979A (zh) * | 2005-06-14 | 2008-07-09 | 安姆根有限公司 | 自缓冲蛋白制剂 |
| RS52106B (sr) * | 2008-02-08 | 2012-08-31 | Biogenerix Ag | Tečni preparat fsh |
-
2005
- 2005-09-27 KR KR1020050089853A patent/KR101105871B1/ko not_active Expired - Lifetime
-
2006
- 2006-09-01 TW TW095132376A patent/TW200735897A/zh unknown
- 2006-09-19 SA SA06270332A patent/SA06270332B1/ar unknown
- 2006-09-21 PE PE2006001144A patent/PE20070437A1/es not_active Application Discontinuation
- 2006-09-25 ES ES06798894T patent/ES2345058T3/es active Active
- 2006-09-25 BR BRPI0616300-9A patent/BRPI0616300A2/pt not_active Application Discontinuation
- 2006-09-25 EP EP06798894A patent/EP1928413B1/en not_active Revoked
- 2006-09-25 WO PCT/KR2006/003811 patent/WO2007037607A1/en not_active Ceased
- 2006-09-25 AT AT06798894T patent/ATE466570T1/de not_active IP Right Cessation
- 2006-09-25 TR TR2008/01968T patent/TR200801968T2/xx unknown
- 2006-09-25 GT GT200600431A patent/GT200600431A/es unknown
- 2006-09-25 JP JP2008532167A patent/JP5364374B2/ja active Active
- 2006-09-25 AU AU2006295570A patent/AU2006295570B2/en active Active
- 2006-09-25 US US12/066,190 patent/US20110201554A1/en not_active Abandoned
- 2006-09-25 RU RU2008111632/15A patent/RU2407514C2/ru active
- 2006-09-25 DE DE602006014175T patent/DE602006014175D1/de active Active
- 2006-09-25 CN CN2006800355835A patent/CN101272764B/zh active Active
- 2006-09-26 AR ARP060104208A patent/AR056538A1/es not_active Application Discontinuation
-
2016
- 2016-05-04 US US15/146,250 patent/US20160243242A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TR200801968T2 (tr) | 2008-06-23 |
| EP1928413A4 (en) | 2008-12-03 |
| WO2007037607A1 (en) | 2007-04-05 |
| EP1928413A1 (en) | 2008-06-11 |
| JP2009509953A (ja) | 2009-03-12 |
| GT200600431A (es) | 2007-08-28 |
| EP1928413B1 (en) | 2010-05-05 |
| ES2345058T3 (es) | 2010-09-14 |
| US20110201554A1 (en) | 2011-08-18 |
| BRPI0616300A2 (pt) | 2011-06-14 |
| CN101272764B (zh) | 2011-05-04 |
| AU2006295570B2 (en) | 2012-08-30 |
| RU2407514C2 (ru) | 2010-12-27 |
| JP5364374B2 (ja) | 2013-12-11 |
| AR056538A1 (es) | 2007-10-10 |
| SA06270332B1 (ar) | 2011-01-15 |
| RU2008111632A (ru) | 2009-10-10 |
| US20160243242A1 (en) | 2016-08-25 |
| ATE466570T1 (de) | 2010-05-15 |
| TW200735897A (en) | 2007-10-01 |
| AU2006295570A1 (en) | 2007-04-05 |
| KR20070035232A (ko) | 2007-03-30 |
| KR101105871B1 (ko) | 2012-01-16 |
| DE602006014175D1 (de) | 2010-06-17 |
| CN101272764A (zh) | 2008-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070437A1 (es) | FORMULACION ACUOSA hFSH | |
| CL2017002488A1 (es) | Formulación farmacéutica estable para administración intratecal que comprende una proteína arilsulfatasa a (asa), sal y un tensoactivo de polisorbato y/o un agente amortiguador, y que además puede contener un agente estabilizante; contenedor que comprende dicha formulación; uso para tratar la enfermedad leucodistrofia metacrómatica (mld). (divisional solicitud 3654-2012) | |
| AR113034A2 (es) | Formulación líquida de un conjugado de la hormona del crecimiento humano de efecto prolongado | |
| AR092470A1 (es) | Formulaciones acuosas estables de adalimumab | |
| AR098830A2 (es) | Suspensiones acuosas estabilizadas para administración parenteral | |
| PE20141384A1 (es) | Composiciones de insulina de accion superrapida | |
| SV2008003071A (es) | Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40 | |
| PE20131324A1 (es) | Formulacion subcutanea de anticuerpo anti-her2 | |
| CL2008003762A1 (es) | Composicion concentrada en suspension acuosa para proteccion de cultivos, que comprende un compuesto activo y como agentes estabilizadores, un disperzante no ionico y un dsipersante anionico y agua; metodos para preparacion de dicha composicion y usos de la misma, para el cuidado de cultivos de interes. | |
| MX2018014631A (es) | Formulacion de neurotoxina. | |
| ES2140444T3 (es) | Composicion y procedimiento para desarrollar viscosidad extensional en composiciones limpiadoras. | |
| PE20151425A1 (es) | Formulaciones farmaceuticas muy concentradas que comprenden un anticuerpo anti-cd20 | |
| AR045068A1 (es) | Formulacion de liberacion inmediata de composiciones farmaceuticas | |
| AR029655A1 (es) | Mejoras en formulaciones en pasta | |
| MX2010004169A (es) | Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo. | |
| ES2531083T3 (es) | Formulaciones estables de polipéptidos y usos de las mismas | |
| MX2021010951A (es) | Composición líquida que comprende un anticuerpo del receptor alfa de interleucina-4 humano. | |
| PE20142314A1 (es) | Composiciones intranasales de dexmedetomidina y metodos de uso de ellas | |
| CY1112106T1 (el) | Σκευασματα παραθυρεοεiδους ορμονης και η χρηση τους | |
| PE20060291A1 (es) | Composiciones farmaceuticas inyectables de posaconazol con particulas estabilizadas | |
| BRPI0418115A (pt) | formulação lìquida estável de hormÈnio de crescimento | |
| AR050152A1 (es) | Dispersion con efecto insecticida y procedimiento para su preparacion | |
| AR050148A1 (es) | Implante y metodo para aumentar y mejorar tejidos | |
| AR039895A1 (es) | Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla | |
| AR056017A1 (es) | Formulaciones de vacuna animal, metodo para preparar una formulacion de vacuna y componente estabilizador de vacuna |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |